Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05087277 Active, not recruiting - COVID-19 Clinical Trials

Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain

Start date: July 20, 2020
Phase:
Study type: Observational

The level of neutralizing antibody was detected by using the constructed pseudovirus covid-19 variant at baseline , 1 month , 6 months and 12 months after primary vaccination, within 15 days after booster immunization at 12 months . and the ability of IgG subclasses to neutralize and cross immunization of variant strains was analyzed.

NCT ID: NCT05080231 Active, not recruiting - COVID-19 Clinical Trials

COVID-19 Immunity Assessment

Start date: July 15, 2021
Phase:
Study type: Observational

The purpose of this study is to collect blood specimens from individuals post infection or post vaccination over time to assess COVID19 Immunity.

NCT ID: NCT05079152 Active, not recruiting - Influenza, Human Clinical Trials

Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

Start date: May 6, 2021
Phase: Phase 4
Study type: Interventional

Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (468 subjects): 1st dose: PPV23 only, 2nd dose: IIV4 only. Blood samples will be collected 3 times: before the 1st dose of vaccinatioin; before the 2nd dose of vaccination; 28 days after the 2nd dose of vaccination. The immunogenicity and safety of both experimental and control groups will be analyzed.

NCT ID: NCT05076227 Active, not recruiting - SARS-CoV2 Infection Clinical Trials

SARS-CoV-2 (COVID-19) Vaccine Tolerability and Clinical Outcome Among Hospital Staff

Start date: January 30, 2021
Phase:
Study type: Observational

Evaluation of the clinical tolerance after the first and second administration of an mRNA vaccine, and depending on the availability of further vaccines, against SARS-CoV-2 for hospital employees. Retrospective analysis of available antibodies against SARS-CoV-2 and results of collected nasopharyngeal specimens for the detection of SARS-CoV-2 (PCR and antigen tests) in hospital employees.

NCT ID: NCT05067959 Active, not recruiting - Covid19 Clinical Trials

Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases

Start date: December 28, 2020
Phase:
Study type: Observational

The 2019-coronavirus disease (COVID-19), caused by SARS-CoV-2, was identified as the source of pneumonia cases in Wuhan city in China. It rapidly spread worldwide and was declared by WHO as a pandemic. COVID-19 vaccines are expected to be the breakthrough in controlling the pandemic. However, studies performed only in healthy adults, and specifically excluded patients who were under immunomodulatory/biologic therapy, thus excluding patients with chronic inflammatory diseases (IBD). In this study we wish to understand vaccine efficacy and immunological response in IBD patients.

NCT ID: NCT05060510 Active, not recruiting - SARS-CoV2 Infection Clinical Trials

The School SPIT Study - COVID-19 Testing in Secondary Schools

Start date: September 14, 2021
Phase: N/A
Study type: Interventional

This study will conduct an evaluation of a program that is being implemented SickKids / Toronto Public health that provides take-home saliva testing kits in schools. Operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. The study will leverage this chance implementation to do a robust evaluation of the public health intervention. Schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. The investigators will evaluate the impact of the program on SARS-CoV-2 case identification in schools.

NCT ID: NCT05057962 Active, not recruiting - COVID-19 Pneumonia Clinical Trials

Tocilizumab in Covid-19 Penumonia in Buenos Aires City

Start date: July 1, 2021
Phase:
Study type: Observational

We conducted a retrospective observational study of adult participants receiving only SOC (dexamethasone 8 mg or its equivalent plus oxygen, HNFO or eventual IMV) versus participants receiving SOC plus TCZ (8mg/kg as a single dose) as treatment for severe or critical SARS CoV2 pneumonia. The inclusion date will be the date of admission, and follow up will conclude at death or discharge (whichever occurs first) to describe clinical and laboratory characteristics and outcome of adult participants receiving only standard of care (SOC) versus participants receiving SOC plus TCZ as treatment for severe or critical SARS CoV2 pneumonia.

NCT ID: NCT05057936 Active, not recruiting - Covid19 Clinical Trials

Antibody After COVID-19 Vaccination

Start date: June 1, 2021
Phase:
Study type: Observational

Chronic kidney disease (CKD) including patients on dialysis and kidney transplant recipients. represents the special subgroups of patients that required protection during the Severe Coronavirus Disease 2019 (COVID-19) pandemic .Since COVID-19 is associated with severe morbidity and mortality in these particular subgroup of patients, the main strategies is proper and rapid vaccination. CKD patients usually have a reduced immune responses, vaccination in these group of patients usually require higher dosage and more frequent dose since the vaccine response is short-lived and less response especially in dialysis patients5 .In patients with normal renal function,the immunity is durable but with modest declines at 6-8months. One study showed a linear decline in IgG in dialysis patients for up to 3months , but there are otherwise limited data. Previous reports of the vaccination in CKD patient involved mainly the mRNA vaccines. The recent reports of seroconversion rate dialysis patients receiving two doses of BNT 162b2 vaccine (Pfizer BioNtech) was lower than in control. In Thailand, the main vaccines available are Coronavac (Sinovac Life Science, Beijing, China) and ChadOx1 nCoV-19 (Oxford-Astra Zeneca) which was dispensed all over the country since April 2021. Data of the efficacy and safety of these vaccines in these patient groups is lacking. Therefore, the aim of this study is to measure the antibody and cellular responses in CKD patients including those with dialysis therapy and kidney transplantation and monitor the adverse events after the first and second doses of after vaccination. The incidence rate of Sars-COV2 infection post vaccination was also observed.

NCT ID: NCT05055505 Active, not recruiting - SARS-CoV2 Infection Clinical Trials

The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions

Start date: September 14, 2021
Phase: N/A
Study type: Interventional

This study will conduct an evaluation of a program that is being implemented SickKids / Toronto Public health that provides take-home saliva testing kits in schools. Operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. This study will leverage this chance implementation to do a robust evaluation of the public health intervention. Schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center, primary care or acute care facility) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. The investigators will evaluate the impact of the program on SARS-CoV-2 case identification in schools.

NCT ID: NCT05055492 Active, not recruiting - SARS-CoV2 Infection Clinical Trials

The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions

Start date: September 14, 2021
Phase: N/A
Study type: Interventional

This study will conduct an evaluation of a program that is being implemented SickKids / Toronto Public Health that provides take-home saliva testing kits in schools. Operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. This study will leverage this chance implementation to do a robust evaluation of the public health intervention. Schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center, primary care or acute care center) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. The investigators will evaluate the impact of the program on SARS-CoV-2 case identification in schools.